Triple receptor agonist · human trial research
What is Retatrutide?
Retatrutide is a peptide designed to activate three hormone receptors: GLP-1, GIP and glucagon. It is therefore described as a triple agonist. Those receptor names describe its mechanism, not three separate medicines mixed together.
How does Retatrutide work?
The targeted pathways are involved in metabolic regulation. Researchers examine how acting on them together affects outcomes such as body weight, glucose regulation and liver fat. A mechanism alone cannot predict the balance of benefits and adverse effects. [1]
What does the research show?
A randomised phase 2a study published in 2024 investigated liver fat and metabolic outcomes in participants with metabolic dysfunction-associated steatotic liver disease. It provides human evidence for the trial population and the preparation used. [1]
What the evidence does not establish
Liver-fat measurements are not the same as proof of long-term protection from liver complications. Results also cannot certify the identity, quality or effects of an independently sold research vial.
Safety questions to discuss
Check the adverse-event information in each trial and confirm current product status with an appropriately qualified professional. This page is not a statement that a particular supplier product is authorised. [2]
Frequently asked questions
Is retatrutide the same as tirzepatide?
No. Tirzepatide targets GIP and GLP-1 receptors; retatrutide also targets the glucagon receptor.
Does a trial result apply to any retatrutide-labelled vial?
No. Trial findings concern a defined preparation, protocol and population.
Sources and further reading
- Retatrutide for metabolic dysfunction-associated steatotic liver disease — randomised phase 2a trial, 2024
- SAHPRA: peptide products public information
These are selected sources, not a systematic review. Check publication dates, study methods and the exact substance tested. Artwork does not establish clinical benefit.